Stem cell treatment and cerebral palsy: Systemic review and meta-analysis

Table 3 Raw motor outcome data

Ref.	Follow-up assessments after intervention (mo)	Change in GMFM-88/66 after 6 mo ± SD	Change in GMFM-88/66 after 12 mo ± SD	% improvement compared to baseline after whole observation period
Chen et al[45], 2013	1, 3, 6	Numbers inaccurately indicated	-	-
Huang et al[46], 2018	3, 6, 12, 24	Control: + 2.96 ± 1.66; MSC: + 7.62 ± 2.44	Control: + 4.75 ± 1.45; MSC: + 10.27 ± 2.96	Control: 5.67%; UCB: 14.89%
Kang et al[47], 2015	1, 3, 6	Control: 3.85 ± 3.75; UCB: 7.08 ± 7.36		Control: 13.1%; UCB: 24.2%
Liu et al[40], 2017	3,6, 12	Control: + 1.85; BMMNC: + 3.1; BMMSC: + 10.45	Control: + 2.91; BMMNC: + 6.46; BMMSC: + 12.52	Control: 7.84%; BMMSC: 33.76%
Luan et al[44], 2012	1, 6, 12	Control: not indicated; NPC: + 8.86	-	-
Min et al[39], 2013	1, 3, 6	Control: + 7.8 ± 5.1; EPO only: + 9.0 ± 6,3; UCB + EPO: + 9.1 ± 6.7	-	No baseline score provided
Rah et al[42], 2017	12 mo after treatment resp. 6 mo for crossover-group	-	Transplantation at baseline: + 2.9; Transplantation after 6 mo: + 6.37	No baseline score provided
Sun et al[41], 2017	12, 24	-	Control: + 6.9 ± 5.5; UCB: + 7.5 ± 6.8 (High dose: improvement + 4.3 ± 1.5 greater than expected. Low-dose and placebo: no significant improvement beyond expectation.)	Control: 13.3%; UCB: 15.3%

BMMNC: Bone marrow mononuclear cells; BMMSC: Bone marrow mesenchymal stem cells; EPO: Erythropoietin; NPC: Neural progenitor cells; UCB: Umbilical cord blood; MSC: Mesenchymal stem cells; GMFM: Gross Motor Function Measure.